Related Experiment Video

Updated: Aug 10, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 31, 2013

Immunotherapy of colon cancer: prospects for developing immunogenic vaccines based on autologous serological typing

H F Oettgen, L J Old

    Cancer
    |March 15, 1980
    PubMed

    Insights

    Developing effective cancer vaccines requires identifying human cancer antigens. Progress in defining antigens for melanoma, kidney, and brain cancers offers new therapeutic vaccine strategies. Colon cancer vaccine development awaits methods for continuous cancer cell culture.

    Area of Science:

    • Oncology
    • Immunology
    • Biotechnology

    Background:

    • Cancer immunotherapy research is limited by the lack of identified human cancer antigens.
    • Significant advancements have been made in defining cell surface antigens for specific cancers.

    Purpose of the Study:

    • To highlight the importance of identifying human cancer antigens for developing effective cancer vaccines.
    • To discuss the potential of recent progress in antigen definition for therapeutic vaccine construction and clinical trials.

    Main Methods:

    • Review of progress in serological definition of cell surface antigens.
    • Discussion of the requirements for applying similar approaches to colon cancer.

    Main Results:

    • Cell surface antigens for malignant melanomas, renal cancers, and astrocytomas have been serologically defined.
    • This definition provides a basis for constructing immunogenic vaccines.

    Conclusions:

    • Further research into human cancer antigens is crucial for advancing cancer therapy.
    • Development of methods for continuous colon cancer cell culture is necessary for applying these vaccine strategies to colon cancer.

    More Related Videos

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

    Published on: January 7, 2019

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    Cancer Vaccines01:30

    Cancer Vaccines

    Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
    Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...